From the FDA Drug Label
It is also marketed for the treatment of premenstrual dysphoric disorder (Sarafem®, fluoxetine hydrochloride).
- Treatment options for Premenstrual Dysphoric Disorder (PMDD) include fluoxetine (PO) 1.
- The drug label mentions that fluoxetine is marketed for the treatment of PMDD, indicating its use as a treatment option.
From the Research
Premenstrual dysphoric disorder (PMDD) treatment typically begins with selective serotonin reuptake inhibitors (SSRIs) as first-line therapy, as they have been shown to be effective in reducing symptoms of PMDD, particularly when taken continuously 2. The most recent and highest quality study, a 2024 systematic review, found that SSRIs probably reduce overall self-rated premenstrual symptoms in women with PMS and PMDD, with moderate-certainty evidence 2. Some key points to consider when treating PMDD include:
- SSRIs, such as fluoxetine, sertraline, or escitalopram, can be taken either continuously or during the luteal phase only (2 weeks before menses) 2
- Hormonal treatments, including combined oral contraceptives containing drospirenone, can also be effective in reducing symptoms of PMDD 3, 4
- Lifestyle modifications, such as regular exercise, stress management techniques, and a balanced diet, can accompany medication and provide additional symptom relief 3
- Calcium and vitamin B6 supplements may also be beneficial in reducing symptoms of PMDD, although the evidence is not as strong as for SSRIs and hormonal treatments 5 It's worth noting that the 2024 study found that SSRIs were probably more effective when taken continuously compared to luteal phase administration, and that they probably increase the risk of adverse events, such as nausea, asthenia, and somnolence 2. Overall, the treatment of PMDD should be individualized and based on the severity of symptoms, medical history, and patient preferences, with a focus on reducing symptoms and improving quality of life 3, 2.